

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				<i>Complete if Known</i> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Application Number</td> <td>10/517,904</td> </tr> <tr> <td>Filing Date</td> <td>December 10, 2004</td> </tr> <tr> <td>First Named Inventor</td> <td>Feng, Jianhua</td> </tr> <tr> <td>Art Unit</td> <td>1651</td> </tr> <tr> <td>Examiner Name</td> <td>Macauley, Sheridan R.</td> </tr> </table>		Application Number	10/517,904	Filing Date	December 10, 2004	First Named Inventor	Feng, Jianhua	Art Unit	1651	Examiner Name	Macauley, Sheridan R.
Application Number	10/517,904														
Filing Date	December 10, 2004														
First Named Inventor	Feng, Jianhua														
Art Unit	1651														
Examiner Name	Macauley, Sheridan R.														
Sheet	1	of	1	Attorney Docket No: FM-10-US											

US PATENT DOCUMENTS					
Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T ²

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		TOKAR; Akt signaling: a damaging interaction makes good; Trends in Biochemical Sciences; 2008; Vol.33, No. 8; pages 356-359; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA	

EXAMINER

DATE CONSIDERED